Drugmaker Eli Lilly and Co. (LLY) announced Monday the appointment of Lucas Montarce as executive vice president and chief financial officer and member of the company's Executive Committee, effective immediately.
Montarce succeeds Anat Ashkenazi, who resigned in June as CFO, to pursue a career opportunity outside of the pharmaceutical industry.
The new CFO, who joined Lilly in 2001, most recently served in the role of Lilly president and general manager for the Spain, Portugal and Greece hub. Previously, Montarce has held a range of finance leadership roles, including group vice president, corporate controller and chief financial officer of Lilly Research Laboratories; vice president, finance and chief financial officer of Lilly International; and vice president, finance and global chief financial officer of Elanco Health.
David Ricks, chair and CEO, said, "Developing leadership talent has always been a strength for Lilly, and Lucas has thrived in a wide variety of roles of increasing scope and impact. Having worked directly with Lucas for more than a decade, I am highly confident he has the drive, curiosity and integrity to excel as our next CFO."
In pre-market activity on the NYSE, Lilly shares were trading at $912.89, up 1.13 percent.
For More Such Health News, visit rttnews.com
For comments and feedback contact: editorial@rttnews.com
Business News
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.